Skip to main content
Janet Dancey Appointed to Lead the NCIC Clinical Trials Group

Janet Dancey Appointed to Lead the NCIC Clinical Trials Group

Last Friday, Alan Harrison, Provost and Vice-Principal (Academic), announced the appointment of Janet Dancey as Director, NCIC-Clinical Trials Group (NCIC-CTG) and holder of the Edith and Carla Eisenhauer Chair in Clinical Cancer Research at Queen’s University.  Speaking on behalf of the search committee, and my co-chair, Christine Williams, VP Research at the Canadian Cancer Society, we could not be more delighted!

Since last April, members of the NCIC-Clinical Trials Group, Canadian Cancer Society and the Faculty of Health Sciences leadership have been engaged in a rigorous, international search for the next head of the NCIC-Clinical Trials Group. Cancer research is a pillar of our research enterprise for the Faculty of Health Sciences, for Queen’s University and for our hospital partners.  It was clearly understood from day one that we had a very important task to complete and I can assure you that the deliberations and review involved in the screening process were exhaustive and intensive.

Janet Dancey requires very little introduction for anyone in the cancer clinical trials sector. A quick scan of her impressive record of scientific achievement will tell you Dr. Dancey is one of this country’s leading oncologic researchers.

Janet’s spectacular accomplishments include: being a full professor at Queen’s (Oncology); being the author or co-author of 141 peer-reviewed publications; being the recipient of the an OICR Scientist Award; leading and participating in studies involving millions of dollars. She has an equally impressive record of leadership, currently dividing her time between NCIC CTG and the Ontario Institute for Cancer Research (OICR). She is Director of Clinical Translational Research at NCIC CTG, Director of the High Impact Clinical Trials Program at OICR, Scientific Director of the Canadian Cancer Clinical Trials Network (3CTN), and Chair of the Experimental Therapeutics Network at Cancer Care Ontario. She will continue her role with the 3CTN.

Janet’s passion for the work, insider knowledge, hands-on experience, breadth and depth of relationships within the group here at Queen’s and every facet of the national operation that add up to the perfect DNA for a next director.

I would like to thank Canadian Cancer Society Vice-President, Christine Williams, Dr. Roger Deeley-Vice Dean Research Queen’s Health Sciences and Director, Queen’s Cancer Research Institute, and the members of the search committee for their hard work and substantial time commitment. I would also like to extend my personal thanks to everyone at the Clinical Trials Group who have gone the extra mile this year during this transition.

Finally, I would like to express my sincere thanks to Dr. Elizabeth Eisenhauer on behalf of Queen’s University for being the Interim Director of NCIC-CTG during our search.  Elizabeth had just settled in as the new Head of the Department of Oncology when we approached her to take on this additional role. Typical of her great dedication, she has taken on the interim directorship at full speed and has provided terrific  leadership during this period of transition. She will remain Interim Director until September 1st.

If you any comments to share about Dr. Dancey or cancer research at Queen’s please comment on the blog… or better yet please drop by the Macklem House, my door is always open.

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.